Cerebrospinal Fluid Phosphorylated Alpha‐Synuclein in Newly Diagnosed Parkinson's Disease
European Journal of Neurology · 2025-06 · 32 (6)
DOI: 10.1111/ene.70167 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 02.06.2025. Verfasst von Camilla Christina Pedersen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway. Hauptthemen laut MEDLINE: Parkinson Disease, alpha-Synuclein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway, Western Norway Regional Health Authority, Norwegian Parkinson Research Foundation.
Abstract (Originalsprache)
Background
Alpha‐synuclein (α‐syn), phosphorylated at serine 129 (pS129‐α‐syn), is a potential biomarker for Parkinson's disease (PD) because it is the predominant α‐syn species found in Lewy bodies.
Methods
We developed an in‐house SIMOA assay, using commercially available components, to quantify pS129‐α‐syn in CSF. The clinical utility of the assay was tested in CSF from 120 patients with PD from the Norwegian ParkWest longitudinal study and 29 normal controls. Prior measurements of CSF total (t)‐α‐syn and the pS129‐α‐syn/t‐α‐syn ratio were included for comparison.
Results
The lower limit of quantification of the in‐house assay used to analyze CSF samples from participants was 0.57 pg/mL, which was well below the observed concentrations of endogenous pS129‐α‐syn in CSF. Median CSF pS129‐α‐syn levels were slightly lower in PD patients compared to controls (5.7 pg/mL vs. 6.5 pg/mL), but the difference was not significant in the unadjusted ( p = 0.404) or adjusted analyses ( p = 0.270). There was no difference in the pS129‐α‐syn/t‐α‐syn ratio between patients and controls. Using linear mixed‐effects models, we found no association between baseline pS129‐α‐syn or the pS129‐α‐syn/t‐α‐syn ratio and motor or cognitive decline over a 10‐year period.
Conclusion
We developed and applied an in‐house SIMOA that reliably quantifies pS129‐α‐syn in CSF samples. This study does not indicate a role for CSF pS129‐α‐syn or the pS129‐α‐syn/t‐α‐syn ratio as clinically useful diagnostic or prognostic biomarkers in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.
- Department of Neurology, Stavanger University Hospital, Stavanger, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- Department of Neurology, Haukeland University Hospital, Bergen, Norway.
ORCID-Profile: Camilla Christina Pedersen, Guido Alves, Ole-Bjørn Tysnes, Jodi Maple-Grødem, Johannes Lange
Förderung
- Research Council of Norway
- Western Norway Regional Health Authority
- Norwegian Parkinson Research Foundation
- Rebergs Legacy
- Nasjonalforeningen for Folkehelsen
- Norges Forskningsråd
- Helse Vest
Zitieren
APA
Pedersen, C. C., Alves, G., Tysnes, O. B., Maple-Grødem, J., & Lange, J. (2025). Cerebrospinal Fluid Phosphorylated Alpha‐Synuclein in Newly Diagnosed Parkinson's Disease. European Journal of Neurology, 32(6). https://doi.org/10.1111/ene.70167
Vancouver
Pedersen CC, Alves G, Tysnes OB, Maple-Grødem J, Lange J. Cerebrospinal Fluid Phosphorylated Alpha‐Synuclein in Newly Diagnosed Parkinson's Disease. European Journal of Neurology. 2025;32(6). doi:10.1111/ene.70167
BibTeX
@article{Pedersen2025,
author = {Pedersen, Camilla Christina and Alves, Guido and Tysnes, Ole-Bjørn and Maple-Grødem, Jodi and Lange, Johannes},
title = {Cerebrospinal Fluid Phosphorylated Alpha‐Synuclein in Newly Diagnosed Parkinson's Disease},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {6},
doi = {10.1111/ene.70167}
}
EUVIMED